Sort
64,565 grants matching “drug discovery”
Center for Biomolecular NMR Data Processing and Analysis
$1,359,008Jeffrey C Hoch · University Of Connecticut Sch Of Med/Dnt · P41 · FY2016 · GM
Molecular And Pharmacological Studies Of Dopamine Receptors
$1,358,962David Sibley · National Institute Of Neurological Disorders And Stroke · ZIA · FY2009 · NS
The NINDS Human Cell and Data Repository (U24 renewal)
$1,358,854Jay Arnold Tischfield · Rutgers, The State Univ Of N.J. · U24 · FY2025 · NS
A Shared Neuroscience Platform for National Dissemination and Training in Brain Organogenesis, Behavioral and Brain Disease Models, Viral Vectors, and Imaging Technologies
$1,358,699Mehrdad Shamloo · Stanford University · U24 · FY2022 · NS
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership
$1,358,485Ernest Martinez · University Of California Riverside · U54 · FY2023 · CA
Developmental Mechanisms of Human Idiopathic Scoliosis
$1,358,310Carol A Wise · Ut Southwestern Medical Center · P01 · FY2023 · HD
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at Vanderbilt
$1,358,025Jeffrey L Neul · Vanderbilt University Medical Center · P50 · FY2024 · HD
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at Vanderbilt
$1,358,023Jeffrey L Neul · Vanderbilt University Medical Center · P50 · FY2022 · HD
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at Vanderbilt
$1,358,023Jeffrey L Neul · Vanderbilt University Medical Center · P50 · FY2023 · HD
Center for Computational Mass Spectrometry
$1,357,906Pavel A Pevzner · University Of California, San Diego · P41 · FY2014 · GM
UCSF Stanford Endometriosis Center for Discovery, Innovation, Training and Community Engagement
$1,357,391Linda C Giudice · University Of California, San Francisco · P01 · FY2025 · HD
NEW DRUG TARGETS FOR APOPTOSIS
$1,357,166University Of Arizona · P01 · FY2003 · CA
Emory Winship Cancer Institute Cancer Center Support Grant
$1,356,978Walter John Curran · Emory University · P30 · FY2011 · CA
Preclinical drug development in pancreatic cancer
$1,356,844Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership
$1,356,807Ernest Martinez · University Of California Riverside · U54 · FY2025 · CA
Biophysical Membrane Mechanisms of Exocytosis inside Extracellular Vesicles, Membrane Repair Failing in Muscular Dystrophy, and Parasite Replication
$1,356,672Joshua Zimmerberg · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2024 · HD
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis
$1,356,315Robert A Lafyatis · University Of Pittsburgh At Pittsburgh · P50 · FY2021 · AR
An integrated translational approach to overcome drug resistance
$1,356,228Ryan Bruce Corcoran · Massachusetts General Hospital · U54 · FY2020 · CA
Cellular and Molecular Physiology of Bloodstream Malaria Parasites
$1,355,835Sanjay A Desai · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Growth Factor Imaging
$1,355,606Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
TARGETING OF TUMOR VASCULATURE
$1,355,391Burnham Institute For Medical Research · P01 · FY2001 · CA
RP2: Targeting genes and pathways for autophagy-dependent inhibition of bacterial infection
$1,355,032Ramnik J Xavier · Ut Southwestern Medical Center · U19 · FY2022 · AI
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy
$1,354,901Zihai Li · Ohio State University · P01 · FY2019 · CA
Identifying resilience proteins in key motor tissues that drive motor and cognitive decline and offset the negative effects of ADRD pathologies within and outside the brain
$1,354,497Aron S Buchman · Rush University Medical Center · R01 · FY2022 · AG
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration
$1,354,462Joseph M Ready · Ut Southwestern Medical Center · RM1 · FY2024 · GM